COMBAT-SHINE is a randomized, double-blind, clinical trial investigating the effect of continuous infusion of prostacyclin (1 ng/kg/min) vs. placebo (saline) for 72 hours in 384 patients with septic shock and SHINE, defined by a plasma concentration of soluble thrombomodulin (sTM) > 10 ng/ml. The primary endpoint is mean daily SOFA score within 90 days of ICU admission. The project is a collaboration between the SHINE Group at Rigshospitalet and the intensive care units at Rigshospitalet 4131, North Zealand Hospital, Bispebjerg Hospital, Hvidovre Hospital and Herlev Hospital together with Center for Health Economics and Policy (CHEP) at Copenhagen University. Primary investigator is Assoc. Prof. M. Bestle, ICU, North Zealand Hospital.